Monthly Multidisciplinary Molecular Tumor Board
August 2020 – June 2021
7:15-8:15 AM PST // 8-9 PM Nepali Time
Presented Virtually Via Webex
Advances in genomic technologies including next generation sequencing (NGS) have fundamentally altered management of cancer patients. Finding a driver gene mutation can lead to specific targeted therapies, which forms the basis for personalized/precision medicine. Proper utilization of these assays must be ensured to maximize benefits to the patient while also being cost-effective.
The Binaytara Foundation will offer a series of twelve multidisciplinary case-based webinars, once a month, on the management of patients with various cancer types, including: Breast Cancer, Chronic Lympocy, Leukemia, Colorectal Cancer, Ovarian Cancer, Cervical Cancer, Acute Leukemia, Hepatolibiary Cancer, Gynecologic Malignancies, Kidney Cancer, Lung Cancer, Multiple Myeloma, Neuroendocrine Tumor, Prostate Cancer
Dr. Siddhartha Yadav
MD & FACP – Mayo Clinic
Genomic medicine has been advancing rapidly since the introduction of next generation sequencing (NGS) technologies. Many commercial vendors as well as academic institutions have been offering extensive molecular testing for cancer care in a clinical setting. The variability
among the current available test options and complex results may be confusing to clinicians and pathologists. With no standards for these tests yet in place, expert review is required to make sense of the test for clinical purposes. This review increases cost to the patient, and slows down the process. Therefore, we see a need in educating those interested on how best to use these tests at hand for different types of cancer.
This activity is supported by independent educational grants from:
- Dova Pharmaceuticals
- Ipsen Pharmaceuticals
Siddhartha Yadav, MD, FACP
Binay Shah, MD